The breakthrough Alzheimer’s drug Lormalzi launched in India by Eli Lilly and Company, is giving fresh hope to patients and doctors battling one of the world’s fastest-growing neurological disorders.
The launch of Lormalzi marks a major step forward in Alzheimer’s treatment because the therapy is designed to slow the progression of the disease instead of only managing symptoms.
Neurologists say the arrival of Lormalzi could transform dementia care in India, especially for patients diagnosed in the early stages of Alzheimer’s disease.
The introduction of Lormalzi comes at a crucial time as India witnesses a steady rise in dementia and age-related cognitive disorders. Experts believe awareness around memory-related illnesses has improved in recent years, but early diagnosis remains one of the country’s biggest healthcare challenges. Doctors are now stressing that therapies like Lormalzi work best when Alzheimer’s is detected before severe brain damage occurs.
Lormalzi contains donanemab, a monoclonal antibody therapy that targets amyloid-beta plaques in the brain. These plaques are considered one of the primary biological markers associated with Alzheimer’s disease. Unlike conventional Alzheimer’s medicines that temporarily improve memory and behavioral symptoms, donanemab directly attacks the underlying disease process by clearing harmful protein buildup from the brain.
Also Read: Building Sustainable Pharma Growth through Ethical Marketing Practices
Medical experts say the therapy is specifically meant for patients with early-stage Alzheimer’s disease, including those with mild cognitive decline and mild dementia caused by Alzheimer’s. Before receiving the treatment, patients must undergo specialized tests such as amyloid PET scans or cerebrospinal fluid analysis to confirm the presence of amyloid plaques.
Doctors across India are calling the therapy a significant scientific advancement but are also warning that patient monitoring is critical during treatment. Lormalzi is administered through monthly intravenous infusions and treatment may continue for up to 18 months depending on clinical response. Patients receiving the drug must undergo regular MRI scans because of potential side effects linked to amyloid-related imaging abnormalities, commonly known as ARIA.
These side effects may include brain swelling, small brain bleeds, headaches, confusion, dizziness, nausea, and vision-related problems. Neurologists have emphasized that only carefully selected patients under specialist supervision should receive the therapy. While the drug has generated excitement globally, doctors continue to caution that Lormalzi is not a cure for Alzheimer’s disease. Instead, it is considered a disease-modifying therapy that may help slow cognitive decline and preserve daily functioning for a longer period.
Healthcare professionals also highlighted the importance of improving dementia awareness in India. Many families still mistake early Alzheimer’s symptoms for normal aging, causing delays in diagnosis and treatment. Experts believe wider screening programs and stronger awareness campaigns are necessary if advanced therapies like Lormalzi are to benefit more patients.
Another major concern surrounding the treatment is affordability. Reports indicate that one 350 mg vial of Lormalzi costs around INR 91,688. Since patients may require multiple infusions over several months, the total treatment cost could range between INR 50 lakh and INR 60 lakh. Doctors and healthcare analysts say the high price may restrict access for many patients in India unless insurance providers and public healthcare systems expand support for dementia care.
The launch of Lormalzi reflects a larger shift in global Alzheimer’s treatment strategies. Over the past few years, pharmaceutical companies and neuroscience researchers have increasingly focused on therapies that target the biological causes of Alzheimer’s rather than simply controlling symptoms.
India’s healthcare sector is also witnessing growing investment in neurological care infrastructure. Hospitals and specialty clinics are expanding access to memory assessment centers, brain imaging technologies, and dementia support services. Experts believe this could improve the diagnosis and management of cognitive disorders in the coming years.
Globally, clinical trials involving anti-amyloid therapies have attracted attention after studies showed modest slowing of cognitive decline in patients with early Alzheimer’s disease. The arrival of Lormalzi in India now places the country among markets adopting next-generation Alzheimer’s treatments.
Doctors and researchers believe therapies like Lormalzi could redefine the future of Alzheimer’s care in India. The focus is gradually moving toward early intervention, precision medicine, and disease-modifying treatments that aim to delay brain deterioration.
However, experts warn that significant barriers still remain. Limited access to advanced diagnostic tests, shortage of trained neurologists, lack of awareness in rural areas, and high treatment costs could slow adoption of such therapies across the country. Healthcare leaders are calling for stronger collaboration between pharmaceutical companies, hospitals, insurance providers, and policymakers to make advanced dementia treatment more accessible.
Researchers are also optimistic that continued progress in neuroscience could lead to safer, more effective, and affordable Alzheimer’s therapies in the future. With India’s elderly population expected to grow rapidly over the next two decades, demand for innovative dementia care solutions is likely to rise sharply.
Founded in 1876, Eli Lilly and Company is a global pharmaceutical company headquartered in the United States. The company focuses on medicines for diabetes, oncology, immunology, and neurological disorders. Lilly has expanded its neuroscience portfolio in recent years through therapies targeting Alzheimer’s disease and other brain-related conditions.
.jpg)
.jpg)
